Two IOP reduction methods from Glaukos showed favorable results and safety profiles in recent trials, according to company press releases.
The iDose TR sustained-release travoprost implant provided substantial IOP reductions in an interim analysis of an ongoing 36-month phase 2b clinical trial, while the iStent infinite trabecular micro-bypass system showed substantial mean diurnal IOP reduction through 12 months.
The iDose TR was evaluated in a 154-subject, multicenter, randomized, double-masked trial designed to evaluate a single administration of one of two iDose TR models compared with twice-daily topical timolol ophthalmic solution 0.5%.
Participants were randomly assigned into fast-release iDose TR, slow-release iDose TR, and timolol active comparator arms. Subjects in either iDose TR arm received a single intracameral implant, while those in the control arm received twice-daily eye drops over the 24-month period.
There was an average reduction in IOP from a baseline of 7.9 mm Hg and 7.4 mm Hg in the fast- and slow-release arms, respectively, vs. 7.8 mm Hg in the control group.
The trial also demonstrated a favorable safety profile, with no clinically significant corneal endothelial cell loss, no serious corneal adverse events, and no adverse conjunctival hyperemia events.
The iStent infinite demonstrated a substantial reduction in mean diurnal IOP in subjects with open-angle glaucoma in a 12-month investigational device exemption pivotal trial.
The prospective, unmasked, the multicenter, single-arm clinical trial enrolled subjects who underwent previous unsuccessful incisional or cilioablative glaucoma surgery and were on maximally tolerated IOP-lowering medications but had uncontrolled IOP. The trial included 72 subjects who received the implant at 15 sites.
Subjects entered the study with a mean baseline IOP of 23.4 mm Hg, with an average of 3.1 medications and two failed surgeries. At 12 months, 76% of subjects had a 20% or greater reduction in mean diurnal IOP from baseline. More than 50% achieved an IOP reduction of 30% or more. The medication burden was reduced by 13%. The safety profile showed no explants, infections, device-related interventions, or hypotony.
more recommended stories
Rare transplant aims to resolve woman’s long bout of cancer
UW Medicine team performs first-in-Pacific Northwest.
Organ transplant recipients can develop immunity after COVID-19, despite immunosuppression
Johns Hopkins Medicine researchers have shown.
Too many donor kidneys are discarded in U.S. before transplantation
When kidneys are removed from deceased.
In Light of Managing Bacterial Keratitis
Bacterial keratitis is an infection of.
Careful IOL selection needed in patients with retinal disease
When we perform cataract surgery for.
Surgical and drug treatment options lead to similar outcomes for diabetic eye disease
Surgical and injectable drug approaches are.
OMSs need research, now more than ever
A recent experience in the operating.
Coating implants with ‘artificial bone’ to prevent inflammation
Bone disease is becoming increasingly prevalent.
Researchers publish the first study on the metagenomics of dental black plaque in adults
The dark pigmentations that appear around.
Chronic pain can be devastating
Chronic pain can be devastating. You.